May Hill Capital LLC Makes New Investment in Haemonetics Co. (NYSE:HAE)

May Hill Capital LLC bought a new position in shares of Haemonetics Co. (NYSE:HAE) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,915 shares of the medical instruments supplier’s stock, valued at approximately $1,399,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Whittier Trust Co. acquired a new stake in Haemonetics during the 4th quarter valued at $62,000. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the period. AlphaQuest LLC lifted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 1,826 shares during the last quarter. KBC Group NV boosted its holdings in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 712 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in Haemonetics in the 3rd quarter valued at about $204,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Raymond James restated a “strong-buy” rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Finally, Needham & Company LLC decreased their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Price Performance

Haemonetics stock opened at $63.65 on Tuesday. The company has a market capitalization of $3.20 billion, a PE ratio of 25.06, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a 50-day moving average price of $65.85 and a two-hundred day moving average price of $74.63. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.